Skip to content

Clinical study of lidocaine combined with hydromorphone for hypopiate analgesia after VATS lobectomy: a randomized controlled study

Clinical study of lidocaine combined with hydromorphone for hypopiate analgesia after VATS lobectomy: a randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070409
Enrollment
Unknown
Registered
2023-04-11
Start date
2023-04-15
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control group:PCIA was used after surgery. The analgesic drug was formulated as hydromorphone 10mg+ Ondansetron 8mg+0.9% normal saline 100ml, background dose 2ml/h, single supplementary dose 2ml, lock
Lidocaine group 1:During anesthesia induction, lidocaine was injected 1mg/kg intravenously (slowly within 10 minutes), and then lidocaine was pumped 1.5mg/kg/h until the patient left the room. The pos
Lidocaine group 2:During anesthesia induction, lidocaine was injected 1mg/kg intravenously (slowly within 10 minutes), and then lidocaine was pumped 1.5mg/kg/h until the patient left the room. The pos

Sponsors

Tai 'an Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. American Society of Anesthesiologists (ASA) Grade 1-2; 3. Sign informed consent to accept postoperative controlled intravenous analgesia (PCIA).

Exclusion criteria

Exclusion criteria: 1. Previous history of chest surgery; 2. Allergic to opioid analgesics; 3. Mental diseases; 4. Severe dysfunction of heart, lung, liver, kidney and other vital organs.

Design outcomes

Primary

MeasureTime frame
Incidence of nausea and vomiting (PONV) within 24 hours after surgery;

Secondary

MeasureTime frame
Postoperative resting and motor pain scores;PONV severity;Recovery time of gastrointestinal function;Related indicators of inflammatory stress response;Immune related indicators;Postoperative skin itching, respiratory depression, and incidence of chronic pain;

Countries

China

Contacts

Public ContactYang Zaiqi

Tai 'an Central Hospital

yang_zaiqi@126.com+86 133 7538 8816

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026